

PRESS RELEASE

ViroGates announces the CE-IVD accreditation of suPARnostic® ELISA on the CHORUS Trio platform marketed by Italy-based DIESSSE

BIRKERØD, DENMARK, 17 February 2022 – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces the successful finalisation of the development project with Italy-based DIESSSE Diagnostica Senese S.p.A. for adaption of suPARnostic® ELISA on DIESSSE's CHORUS Trio platform.

ViroGates announced on 6th December 2021 ([Company announcement 23-2021](#)) that ViroGates and DIESSSE would embark on a project to make suPARnostic® available on DIESSSE's CHORUS Trio platform for the triage of patients with COVID-19 disease in adults with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure.

Patients identified with suPARnostic® levels above 6 ng/ml may subsequently be treated with Kineret® (anakinra) a pharmaceutical product marketed by Swedish Sobi ([EMA Label approval](#)).

CHORUS suPAR is performed in the serum and plasma of COVID-19 patients, delivering the results in less than one hour, and is used to evaluate the severity of the infection and as companion diagnostic for the selection of patients eligible for treatment with Anakinra.

CHORUS suPAR now has the full CE-IVD accreditation.

The CHORUS platform is particularly suited for batch collection and analysis of suPAR on a small to medium amount of samples. It will be important in handling COVID-19 samples in many hospitals that do not have access or capacity to run high-throughput systems like the suPARnostic® TurbiLatex.

The CHORUS Trio system has over 150 available tests in more than 3,000 clinical units ranging from hospitals to larger health clinics in approximately 100 countries

CEO Jakob Knudsen says in a comment: *"We are excited that our suPARnostic® product can now be brought to a broader range of customers and also that we*

can tap into DIESSSEs installed base in hospitals where our other suPARnostic® product lines may not be available. This product will complement our existing portfolio in segments that would otherwise be difficult for us to reach.”

Massimiliano Boggetti, CEO of DIESSSE, says: *“I am very proud that my scientists, in a joint effort with the Research and Development team of ViroGates, have been able to optimise the suPARnostic® kit on the CHORUS platform in less than three months of hard work. A clear sign of dynamism and great cooperation between the two companies.”*

DIESSSE Diagnostica Senese S.p.A.

DIESSSE is an Italian company with an integrated and entirely inhouse production of in vitro diagnostic systems. Its headquarters are in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems primarily in the field of immunodiagnosics and automatic measurement of erythrocyte sedimentation rate (ESR). The company has a global presence in over 100 countries, three production sites and a research centre where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, making Diesse synonymous with “Diagnostics Evolution”. Link to the [Chorus Trio system](#)

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, France and Benelux, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is a biomarker detected by ViroGates' suPARnostic® products. It is a protein found in the plasma. suPAR is considered a general risk status biomarker indicating inflammation and can indicate disease presence, severity, and progression across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 800 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalisation or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics'



Diagnostica Senese S.p.A.

www.diesse.it



cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.

DIESE Press Office:

Federica Casiraghi – DIESE Diagnostica Senese
Tel. +39 342 9511925 – federicacasiraghi@diesse.it

ViroGates A/S:

CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se